These defects impact plasma membrane functionality and endosomal recycling of multiple oncogenic receptors, such as HER2 and transferrin receptors.<h4>Conclusions</h4>These data collectively identify BLVRB as a novel metabolic target in breast cancer, distinct from other redox-regulating pathways. This evidence concerns the gene ERBB2 and breast cancer.